Abstract

Background IL20RB, interleukin 20 receptor subunit beta, functions as a cytokine receptor subunit coding gene and has been discovered to serve an essential function in human malignancies. However, the link between IL20RB expression, clinical outcomes, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC) remains unclear. Methods The Cancer Genome Atlas (TCGA) was utilized to compile data on the IL20RB expression in both normal and ccRCC tissues. The link between IL20RB expression and clinicopathologic characteristics was examined utilizing the TCGA database. Kaplan-Meier survival curves were employed for performing the survival analysis. Furthermore, a protein network involving IL20RB was established using data from the GeneMANIA database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were undertaken, and the relationship between IL20RB and tumor immune infiltration was examined via single-sample GSEA (ssGSEA). Additional examination of the link between tumor-infiltrating immune cells (TIIC) and IL20RB was executed utilizing the Tumor Immune Estimation Resource (TIMER) and TISIDB databases. IL20RB expression in tumor specimens was detected through immunohistochemistry (IHC). IL20RB expression levels in tumor cells were confirmed via Western blot analysis. Cell counting kit-8 (CCK-8) and colony formation assays evaluated IL20RB’s impact on ccRCC cell viability. Wound Healing and Transwell assays assessed IL20RB’s influence on ccRCC cell migration. Results Peritumor samples exhibited notably reduced IL20RB expression compared to ccRCC samples. IL20RB expression levels correlated markedly with sample classification, lymph node status, tumor differentiation, and disease progression. Enhanced IL20RB expression is linked to poor Disease-Specific Survival (DSS) and Overall Survival (OS) in ccRCC patients ( p < 0.01). Subsequently, a significant link was observed between IL20RB overexpression and immunomodulators, chemokines,